A New $16,000 Postpartum Despair Drug Is Right here. How Will Insurers Deal with It?


A much-awaited remedy for postpartum despair, zuranolone, hit the market in December, promising an accessible and fast-acting treatment for a debilitating sickness. However most personal well being insurers have but to publish standards for when they are going to cowl it, in keeping with a brand new evaluation of insurance coverage insurance policies.

The dearth of steering might restrict use of the drug, which is each novel — it targets hormone perform to alleviate signs as a substitute of the mind’s serotonin system, as typical antidepressants do — and costly, at $15,900 for the 14-day capsule routine.

Attorneys, advocates, and regulators are watching carefully to see how insurance coverage firms will form insurance policies for zuranolone due to how some dealt with its predecessor, an intravenous type of the identical drug known as brexanolone, which got here available on the market in 2019. Many insurers required sufferers to strive different, cheaper drugs first — generally known as the fail-first strategy — earlier than they may very well be authorized for brexanolone, which was proven in early trials reviewed by the FDA to offer reduction inside days. Typical antidepressants take 4 to 6 weeks to take impact.

“We’ll should see if insurers cowl this drug and what fail-first necessities they put in” for zuranolone, stated Meiram Bendat, a licensed psychotherapist and an legal professional who represents sufferers.

Most well being plans have but to problem any pointers for zuranolone, and maternal well being advocates fear that the few which have are taking a restrictive strategy. Some insurance policies require that sufferers first try to fail a typical antidepressant earlier than the insurer can pay for zuranolone.

In different instances, pointers require psychiatrists to prescribe it, fairly than obstetricians, probably delaying remedy since OB-GYN practitioners are often the primary medical suppliers to see indicators of postpartum despair.

Advocates are most anxious concerning the lack of protection steering.

“For those who don’t have a broadcast coverage, there may be going to be extra variation in decision-making that isn’t honest and is much less environment friendly. Transparency is basically necessary,” stated Pleasure Burkhard, government director of the nonprofit Coverage Heart for Maternal Psychological Well being, which commissioned the research.

With brexanolone, which was priced at $34,000 for the three-day infusion, California’s largest insurer, Kaiser Permanente, had such rigorous standards for prescribing it that consultants stated the coverage amounted to a blanket denial for all sufferers, in keeping with an NPR investigation in 2021.

KP’s written pointers required sufferers to try to fail 4 drugs and electroconvulsive remedy earlier than they’d be eligible for brexanolone. As a result of the drug was authorized just for as much as six months postpartum, and trials of typical antidepressants take 4 to 6 weeks every, the clock would run out earlier than a affected person had time to strive brexanolone.

An evaluation by NPR of a dozen different well being plans on the time confirmed Kaiser Permanente’s coverage on brexanolone to be an outlier. Some did require that sufferers fail one or two different medicine first, however KP was the one one which really helpful 4.

Miriam McDonald, who developed extreme postpartum despair and suicidal ideation after giving start in late 2019, battled Kaiser Permanente for greater than a 12 months to seek out efficient remedy. Her medical doctors put her on a merry-go-round of medicines that didn’t work and infrequently carried insufferable unwanted effects, she stated. Her medical doctors refused to prescribe brexanolone, the one FDA-approved treatment particularly for postpartum despair on the time.

“No girl ought to endure like I did after having a toddler,” McDonald stated. “The coverage was fully unfair. I used to be in purgatory.”

One month after NPR revealed its investigation, KP overhauled its standards to advocate that girls strive only one treatment earlier than turning into eligible for brexanolone.

Then, in March 2023, after the federal Division of Labor launched an investigation into the insurer — citing NPR’s reporting — the insurer revised its brexanolone pointers once more, eradicating all fail-first suggestions, in keeping with inside paperwork not too long ago obtained by NPR. Sufferers want solely decline a trial of one other treatment.

“Since brexanolone was first authorized to be used, extra expertise and analysis have added to details about its efficacy and security,” the insurer stated in an announcement. “Kaiser Permanente is dedicated to making sure brexanolone is offered when physicians and sufferers decide it’s an applicable remedy.”

“Kaiser mainly went from having essentially the most restrictive coverage to essentially the most strong,” stated Burkhard of the Coverage Heart for Maternal Psychological Well being. “It’s now a gold normal for the remainder of the trade.”

McDonald is hopeful that her willingness to talk out and the next regulatory actions and coverage modifications for brexanolone will lead Kaiser Permanente and different well being plans to set patient-friendly insurance policies for zuranolone.

“This may forestall different ladies from having to undergo a 12 months of despair to seek out one thing that works,” she stated.

Clinicians have been excited when the FDA authorized zuranolone final August, believing the capsule type, taken as soon as a day at house over two weeks, will probably be extra accessible to ladies in contrast with the three-day hospital keep for the IV infusion. Many perinatal psychiatrists instructed NPR it’s crucial to deal with postpartum despair as rapidly as doable to keep away from unfavourable results, together with cognitive and social issues within the child, nervousness or despair within the father or accomplice, or the dying of the mom to suicide, which accounts for as much as 20% of maternal deaths.

To this point, solely one of many nation’s six largest personal insurers, Centene, has set a coverage for zuranolone. It’s unclear what standards KP will set for the brand new capsule. California’s Medicaid program, generally known as Medi-Cal, has not but established protection standards.

Insurers’ insurance policies for zuranolone will probably be written at a time when the regulatory surroundings round psychological well being remedy is shifting. The U.S. Division of Labor is cracking down on violations of the Psychological Well being Parity and Habit Fairness Act of 2008, which requires insurers to cowl psychiatric therapies the identical as bodily therapies.

Insurers should now adjust to stricter reporting and auditing necessities supposed to extend affected person entry to psychological well being care, which advocates hope will compel well being plans to be extra cautious concerning the insurance policies they write within the first place.

In California, insurers should additionally adjust to a good broader state psychological well being parity legislation from 2021, which requires them to make use of clinically based mostly, expert-recognized standards and pointers in making medical choices. The legislation was designed to restrict arbitrary or cost-driven denials for psychological well being therapies and has been hailed as a mannequin for the remainder of the nation. A lot-anticipated laws for the legislation are anticipated to be launched this spring and will supply additional steering for insurers in California setting insurance policies for zuranolone.

Within the meantime, Burkhard stated, sufferers affected by postpartum despair shouldn’t maintain again from asking their medical doctors about zuranolone. Insurers can nonetheless grant entry to the drug on a case-by-case foundation earlier than they formalize their protection standards.

“Suppliers shouldn’t be deterred from prescribing zuranolone,” Burkhard stated. 

KFF Well being Information is a nationwide newsroom that produces in-depth journalism about well being points and is likely one of the core working applications at KFF—an impartial supply of well being coverage analysis, polling, and journalism. Be taught extra about KFF.


This story might be republished at no cost (particulars).


Please enter your comment!
Please enter your name here